Skip to main content

Table 1 Baseline characteristics of the linked sample of trial participants as collected in the CHHiP trial. The linked sample is representative of the overall trial population [28]. P-values are calculated using independent sample t-test, Mann–Whitney or chi-squared tests. IQR, interquartile range

From: Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice

  CHHiP unlinked sample
n = 3110
Linked sample
N = 106
P-value
Age at randomisation to CHHiP (years)
 Median (IQR) 69 (64–73) 70 (65–74) 0.13
 Range 48–85 44–82  
Randomisation, n (%)    0.04
 Group 1 (standard schedule, 74Gy/37f) 1041 (33) 24 (23)  
 Group 2 (hypofractionated schedule 1, 60Gy/20f) 1029 (33) 45 (42)  
 Group 3 (hypofractionated schedule 2, 57Gy/19f) 1040 (33) 37 (35)  
Clinical T stage, n (%)    0.10
 T1 1125 (36) 45 (42)  
 T2 1718 (55) 48 (45)  
 T3 264 (9) 13 (12)  
 Missing or unknown 3 (< 1) 0 (0)  
Type of androgen deprivation therapy, n (%)    0.66
 Luteinising-hormone-releasing hormone plus short-term anti-androgen 2608 (84) 92 (87)  
 Bicalutamide (150 mg) 393 (13) 10 (9)  
 Other 9 (< 1) 0 (0)  
 None 86 (3) 4 (4)  
Time from start of androgen deprivation therapy to radiotherapy, median (IQR), (weeks) 16 (14–20) 17 (14–21) 0.29
Past clinical history of comorbidity, n (%)
 Diabetes 333 (11) 9 (8) 0.57
 Hypertension 1238 (40) 38 (36) 0.47
 Inflammatory bowel disease 122 (4) 2 (2) 0.42
 Symptomatic haemorrhoids 204 (7) 5 (5) 0.58
Previous pelvic surgery, n (%) 244 (8) 8 (7) 1.00
Previous transurethral resection of the prostate, n (%) 243 (8) 16 (15) 0.01
Alpha-blockers or anticholinergic drugs at trial entry, n (%) 363 (12) 12 (11) 1.00
Year of entry to the CHHiP trial, n (%)    0.65
 Year 2–3 106 (3) 2 (2)  
 Year 4–5 258 (8) 11 (10)  
 Year 6–7 521 (17) 17 (16)  
 Year 8–9 1338 (43) 41 (39)  
 Year 10–11 886 (28) 35 (33)